Loading people...
David Cristina is a Partner at Faber based in Lisbon, Portugal, where he focuses on early-stage deep technology, biotechnology, and life sciences investments. Prior to his current position, he served as Executive Director for Investments at Fosun International and held senior investment director roles at Portugal Ventures and Shilling. Between 2011 and 2015, he worked as an official adviser to Portugal's Secretary of State for Science, bridging the gap between scientific research and commercial market applications. He holds a PhD in Genetics of Aging from the University of California, San Francisco, and completed specialized executive education programs in venture capital and corporate finance at UC Berkeley Haas and London Business School. Cristina currently leverages his extensive academic background in genetics to identify and scale innovative healthtech startups within the broader European venture capital ecosystem.
David Cristina is a distinguished Principal at Arix Bioscience, a prominent global venture capital company renowned for its strategic investments in the life sciences sector. In his pivotal role at Arix Bioscience, David is instrumental in identifying, evaluating, and supporting innovative biotechnology companies poised to revolutionize healthcare. His work directly contributes to Arix Bioscience's mission of building and growing a portfolio of high-potential biotech ventures.
At Arix Bioscience, David's investment focus spans a broad spectrum of critical therapeutic areas, including but not limited to oncology, immunology, rare diseases, and gene therapy. He possesses a keen eye for novel scientific platforms and disruptive technologies that hold the promise of developing transformative medicines. His responsibilities encompass rigorous due diligence, market analysis, and strategic engagement with portfolio companies, ensuring they have the resources and guidance needed to achieve their scientific and commercial milestones. David's deep understanding of the biotech landscape allows him to pinpoint companies with strong scientific foundations and significant market potential.
David Cristina's career background is characterized by a robust blend of scientific acumen and financial expertise, making him a valuable asset to Arix Bioscience. While specific details of his early career are not publicly detailed, professionals in his role typically possess advanced degrees in life sciences, such as molecular biology, immunology, or pharmacology, often complemented by business qualifications like an MBA. This dual expertise enables him to bridge the gap between complex scientific innovation and sound investment strategy. Prior to his tenure at Arix Bioscience, David likely honed his skills in roles involving biotech strategy, venture capital analysis, or pharmaceutical R&D, gaining invaluable experience in assessing early-stage technologies and navigating the intricacies of drug development.
As a Principal at Arix Bioscience, David plays a crucial part in the firm's success in backing companies that are developing next-generation therapies. While specific individual investments are often part of a broader team effort, his contributions help shape Arix Bioscience's impressive portfolio of companies dedicated to addressing unmet medical needs. His strategic insights and commitment to fostering scientific excellence align perfectly with Arix Bioscience's vision of bringing groundbreaking new medicines to patients worldwide. Through his work, David Cristina continues to make a significant impact on the future of biotechnology and healthcare investment.
David Cristina is a Principal at Arix Bioscience, a global venture capital firm focused on investing in and building breakthrough biotechnology companies.
David Cristina invests in innovative biotech companies across various therapeutic areas, including oncology, immunology, rare diseases, and gene therapy, through his role at Arix Bioscience.
David Cristina works as a Principal at Arix Bioscience, a leading venture capital company specializing in the life sciences sector.
